ATE423220T1 - Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen - Google Patents

Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen

Info

Publication number
ATE423220T1
ATE423220T1 AT00986492T AT00986492T ATE423220T1 AT E423220 T1 ATE423220 T1 AT E423220T1 AT 00986492 T AT00986492 T AT 00986492T AT 00986492 T AT00986492 T AT 00986492T AT E423220 T1 ATE423220 T1 AT E423220T1
Authority
AT
Austria
Prior art keywords
compounds
decay
nonsense
termination
rns
Prior art date
Application number
AT00986492T
Other languages
English (en)
Inventor
Holger Beckmann
Marc Learned
Stuart Peltz
Kevin Czaplinski
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Application granted granted Critical
Publication of ATE423220T1 publication Critical patent/ATE423220T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Detection And Correction Of Errors (AREA)
AT00986492T 1999-12-14 2000-12-13 Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen ATE423220T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/461,508 US6458538B1 (en) 1999-12-14 1999-12-14 Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay

Publications (1)

Publication Number Publication Date
ATE423220T1 true ATE423220T1 (de) 2009-03-15

Family

ID=23832841

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986492T ATE423220T1 (de) 1999-12-14 2000-12-13 Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen

Country Status (8)

Country Link
US (3) US6458538B1 (de)
EP (2) EP2036991A1 (de)
JP (1) JP4683808B2 (de)
AT (1) ATE423220T1 (de)
AU (1) AU784947B2 (de)
CA (1) CA2394470C (de)
DE (1) DE60041592D1 (de)
WO (1) WO2001044516A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
WO2002083862A2 (en) * 2001-04-13 2002-10-24 Johns Hopkins University School Of Medicine Methods and compositions for identifying disease genes using nonsense-mediated decay inhibition
CA2448165A1 (en) * 2001-05-23 2002-11-28 Axel Ullrich Pyruvate-kinase as a novel target molecule
US20030049666A1 (en) * 2001-07-31 2003-03-13 University Of Utah Tissue culture assay for measuring drug induced translational recoding at premature stop codons and frameshift mutations
JP2004538002A (ja) * 2001-08-02 2004-12-24 アルタナ　ファルマ　アクチエンゲゼルシャフト 停止コドン抑制による組み換え遺伝子発現の新規方法
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
EP1525185A1 (de) * 2002-07-24 2005-04-27 PTC Therapeutics, Inc. Acetylaminobenzoesäure-verbindungen und deren verwendung zur nonsense-unterdrückung und behandlung von krankheiten
AU2003252136A1 (en) * 2002-07-24 2004-02-09 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLEDULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US20060154883A1 (en) * 2002-08-22 2006-07-13 Maquat Lynne E Nonsense-mediated mrna decay
EP3345895B1 (de) 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazolbenzoesäureverbindung und deren verwendung zur nonsense-unterdrückung und behandlung von krankheiten
KR100554514B1 (ko) * 2003-12-26 2006-03-03 삼성전자주식회사 반도체 장치에서 패턴 형성 방법 및 이를 이용한 게이트형성방법.
EP1716233B1 (de) * 2004-01-30 2009-08-26 Maxygen Holdings Ltd. Gesteuertes überlesen von stopcodons
WO2005086768A2 (en) * 2004-03-11 2005-09-22 Albert Einstein College Of Medicine Of Yeshiva University Enhanced production of functional proteins from defective genes
GB0525492D0 (en) 2005-12-15 2006-01-25 Univ Dundee Filaggrin
US20070144045A1 (en) * 2005-12-23 2007-06-28 Lexmark International, Inc. Electroluminescent display system
GB0600948D0 (en) * 2006-01-18 2006-02-22 Univ Dundee Prevention/Treatment Of Ichthyosis Vulgaris, Atopy And Other Disorders
RU2462246C2 (ru) 2006-03-30 2012-09-27 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы получения функционального белка из днк, имеющей нонсенс-мутацию, и лечения нарушений, ассоциированных с ней
US20100267712A1 (en) 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
EP2251437B1 (de) 2009-05-13 2013-12-04 Hannelore Breitenbach-Koller Verfahren zur Identifizierung von Verbindungen, die die translationale Aktivität von ribosomalen Proteinen in differentieller mRNA-Expression steuern
WO2012021707A2 (en) * 2010-08-11 2012-02-16 The Regents Of The University Of California Premature-termination-codons readthrough compounds
US9216180B2 (en) 2012-10-02 2015-12-22 New York University Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
MX2015008146A (es) 2012-12-24 2016-01-20 Univ Ramot Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas.
CA2987980A1 (en) 2015-06-05 2016-12-08 Ptc Therapeutics, Inc. Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease
WO2017112954A1 (en) 2015-12-23 2017-06-29 Moonshot Pharma Llc Methods for inducing an immune response by promoting premature termination codon read-through
CN105928913A (zh) * 2016-04-14 2016-09-07 天津中医药大学 一种基于细胞表型的高内涵多指标肾毒性的检测方法及其应用
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
WO2022204471A1 (en) * 2021-03-26 2022-09-29 Ptc Therapeutics Inc. Regulation of transgene expression using a small molecule inducible splicing switch

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1176332B (it) * 1984-06-27 1987-08-18 Erba Farmitalia Procedimento per al preparazione di peptidi
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5015570A (en) * 1988-05-13 1991-05-14 Molecular Therapeutics, Inc. Molecular diagnosis of Alzheimer Disease
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5998603A (en) * 1994-09-29 1999-12-07 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analogs, and oligomers thereof
WO1993018165A1 (en) * 1992-03-02 1993-09-16 The Board Of Trustees Of The Leland Stanford Junior University Microorganisms having attenuated invasiveness
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6391542B1 (en) * 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
ES2289194T3 (es) * 1993-05-27 2008-02-01 Aventis Pharmaceuticals Inc. Bibliotecas en fase solida codificadas, segregadas topologicamente.
US5641627A (en) * 1993-10-25 1997-06-24 Ribogene, Inc. Methods for screening for antimycotics
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5643722A (en) * 1994-05-11 1997-07-01 Trustees Of Boston University Methods for the detection and isolation of proteins
US5650316A (en) * 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6071700A (en) * 1995-01-20 2000-06-06 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated MRNA decay functions
US5593835A (en) * 1995-05-12 1997-01-14 President And Fellows Of Harvard College Methods and kits for RNA binding compounds
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
WO1997009342A1 (en) * 1995-09-08 1997-03-13 Scriptgen Pharmaceuticals, Inc. Screen for compounds with affinity for rna
US5666341A (en) * 1995-09-18 1997-09-09 Matsushita Electric Industrial Co., Ltd. Data detection apparatus
US5840702A (en) * 1996-03-22 1998-11-24 Uab Research Foundation Cystic fibrosis treatment
US6004749A (en) * 1996-07-31 1999-12-21 Message Pharmaceuticals Method for identifying compounds affecting RNA/RNA binding protein interactions
US6107029A (en) * 1996-07-31 2000-08-22 Message Pharmaceticals, Inc. Universal method for detecting interactions between RNA molecules and RNA binding proteins
US6060240A (en) * 1996-12-13 2000-05-09 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
AU1114099A (en) * 1997-10-21 1999-05-10 University Of Massachusetts Heterologous polypeptide production in the absence of nonsense-mediated mrna decay function
US6211477B1 (en) * 1998-02-26 2001-04-03 Becton Dickinson And Company Electrostatic deceleration system for flow cytometer
US6428956B1 (en) * 1998-03-02 2002-08-06 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
US6207391B1 (en) * 1998-03-31 2001-03-27 Tularik Inc. High-throughput screening assays for modulators of STAT4 and STAT6 activity
MXPA00011690A (es) * 1998-05-26 2002-10-17 Univ New Jersey Med Sistema para reproducir y modular la estabilidad y recambio de moleculas de arn.
MXPA00011760A (es) * 1998-05-28 2002-10-17 Univ New Jersey Med Metodo para modular la eficiencia de terminacion de traduccion y degradacion de arn mensajero aberrante, que incluye un complejo de vigilancia que comprende upf1p de humana, factor de liberacion eucariotico 1 y factor de liberacion eucariotico 3.
WO2000005586A2 (en) * 1998-07-22 2000-02-03 University Of Medicine And Dentistry Of New Jersey Rna helicases modulating translation termination
US6420109B1 (en) * 1998-09-11 2002-07-16 Genelabs Technologies, Inc. Nucleic acid ligand interaction assays
US6147344A (en) * 1998-10-15 2000-11-14 Neogenesis, Inc Method for identifying compounds in a chemical mixture
WO2000036151A1 (en) * 1998-12-14 2000-06-22 Li-Cor, Inc. A heterogeneous assay for pyrophosphate detection
ATE432993T1 (de) * 1999-10-04 2009-06-15 Univ New Jersey Med Tar rna bindende peptide
US6458538B1 (en) * 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
AU2003247610A1 (en) * 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
CA2493816A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
CA2493458A1 (en) * 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
US7291603B2 (en) * 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
EP3345895B1 (de) * 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazolbenzoesäureverbindung und deren verwendung zur nonsense-unterdrückung und behandlung von krankheiten
DE112005000806T5 (de) * 2004-03-29 2007-04-05 Automotive Systems Laboratory, Inc., Armada Gaserzeugungsmittel und Verfahren zu dessen Herstellung
US7379842B2 (en) * 2005-01-25 2008-05-27 Drop Zone Corp. Hang timer for determining time of flight of an object
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
WO2001044516A2 (en) 2001-06-21
DE60041592D1 (de) 2009-04-02
US20030008317A1 (en) 2003-01-09
JP2003516767A (ja) 2003-05-20
AU784947B2 (en) 2006-08-03
US20060134681A1 (en) 2006-06-22
CA2394470A1 (en) 2001-06-21
EP2036991A1 (de) 2009-03-18
EP1238110B1 (de) 2009-02-18
US7026122B2 (en) 2006-04-11
CA2394470C (en) 2011-08-09
AU2272001A (en) 2001-06-25
US6458538B1 (en) 2002-10-01
EP1238110A2 (de) 2002-09-11
JP4683808B2 (ja) 2011-05-18
WO2001044516A3 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
ATE423220T1 (de) Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen
AU8072898A (en) Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
BG105957A (en) Radiolabeling kit and binding assay
DE60136487D1 (de) Verfahren und vorrichtung für eine dentaleinheit
HK1040533A1 (zh) 监察蛋白脢体抑制剂药物活动的方法
EP1035215A3 (de) Verfahren und Sondenset zur Erkennung von Krebs
MXPA03004913A (es) Usos de genes de mamifero y reactivos relacionados.
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
BR9907161A (pt) Uso de um ensaio quanto à adenilato quinase em um teste in vitro, processos para determinar a suscetibilidade de uma bactéria a um reagente, para determinar a sensibilidade de uma bactéria a um antibiótico ou agente bioestático, para determinar a fase de cultivo de uma cultura bacteriana , e, kit de teste para analisar a sensibilidade de bactérias a antibióticos
AU4287599A (en) Computerized tomography for non-destructive testing
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
MXPA01011182A (es) Metodos, composiciones y conjuntos para indicador biologico de esterilizacion.
AU7410600A (en) Method for the determination of substances using the evanescence field method
ATE384952T1 (de) Enzymhemmungsimmunverfahren
ATE199184T1 (de) Testverfahren
WO2000075363A3 (en) Enzymatic measurement of mycophenolic acid
MX2007012486A (es) Ensayos de investigacion sobre estilbazio.
BR0014626A (pt) Análise de leptina
ATE285581T1 (de) Assay-verfahren
DE69913533D1 (de) Reagentien für cyp2d fluoreszenztest
AU2001250987A1 (en) Methods for detecting inflammation and inflammatory conditions
IL138756A0 (en) Apparatus and method for cancer detection
WO2001026536A3 (en) Methods of diagnosing and treating hepatic cell proliferative disorders
AU5527000A (en) Method, composition and testing device for the qualitative and quantitative determination of peroxides, in particular, hydrogen peroxide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties